RAD001 and Bicalutamide for Androgen Independent Prostate Cancer

Phase 2 Completed 36 enrolled Dana-Farber Cancer Institute Beth Israel Deaconess Medical Center · collab Novartis Pharmaceuticals · collab

NaSingle-groupOpen-labelTreatment

Summary

In the treatment of castration-resistant prostate cancer (CRPC), therapies will long response durations remain elusive as a result of the inherent ability of prostate cancer cells to develop iterative resistance. The goal of this study is to learn if the study drug RAD001 together with Bicalutamide can slow the growth of prostate cancer. The safety of the combination will also be studied.

Timeline

Start: 2008-02
Primary completion: 2012-05
Completion: 2012-05

Publications

Results Nakabayashi M, Werner L, Courtney KD, Buckle G, Oh WK, Bubley GJ, Hayes JH, Weckstein D, Elfiky A, Sims DM, Kantoff PW, Taplin ME. Phase II trial of RAD001 and bicalutamide for castration-resistant prostate cancer. BJU Int. 2012 Dec;110(11):1729-35. doi: 10.1111/j.1464-410X.2012.11456.x. Epub 2012 Aug 29.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Bicalutamide	Other / unclassified	50 mg	—
Subject	Everolimus	Small molecule	10 mg	—

RAD001 and Bicalutamide for Androgen Independent Prostate Cancer

Summary

Timeline

Publications

Drugs

Indications